Continuous Bioprocessing Market by Product (Filtration, Chromatography, Centrifuges, Consumables), Application (Commercial {Vaccines, Monoclonal Antibodies}, R&D), End User (Pharmaceuticals, Biotechnology, CROs), and Geography - Forecast to 2027
The global continuous bioprocessing market is expected to grow at a CAGR of 23.0% from 2020 to 2027 to reach $348.9 million by 2027.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, challenges, and opportunities. Some of the major factors driving this market's growth include the growing demand for biopharmaceuticals, technological developments in continuous bioprocessing, product launches in the area of continuous bioprocessing, and global initiatives supporting the adoption of biopharmaceuticals. The growing shift towards the bioprocess 4.0 industry, growing opportunities in developing countries, and rising preference for personalized medicine are expected to create significant market growth opportunities.
Based on product, the filtration systems and consumables segment accounted for the largest share of the market in 2020. The growing demand for higher standards of filter operations in biopharma manufacturing is one of the major drivers for the growth of this segment. Filter manufacturers are developing filtration technologies for continuous bioprocessing to achieve both separation and purification through a combination of physical removal capabilities of filtration and size exclusion.
Based on application, the research and development segment is expected to grow at the highest CAGR during the forecast period. The rising focus of R&D to develop vaccines and suitable therapies for COVID-19 and growing relevance of mAb manufacturing for the treatment of various diseases are driving the market growth. The R&D in cell and gene therapy is also accelerated, with over 900 candidates in clinical studies. Facility expansions of CROs or CDMOs to advance research in these areas are expected to boost market growth.
Based on end user, the CDMOs and CROs segment is expected to grow at the highest CAGR during the forecast period. Rising investments in CDMOs and CROs and the gradual shifting of CDMOs from batch to continuous manufacturing are driving the market growth.
An in-depth analysis of the continuous bioprocessing market's geographical scenario provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2020, North America commanded the largest share of the global continuous bioprocessing market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The factors such as an established healthcare system in North America, greater adoption of advanced technologies, growth in pharmaceutical research & development, and strong presence of key players are contributing to the largest share of this region.
Some of the key players operating in the global continuous bioprocessing market are 3M (U.S.), Cytiva (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), Repligen Corporation (U.S.), Eppendorf AG (Germany), Applikon Biotechnology (Netherlands), Pall Corporation (U.S.), and Bionet (Spain).
The global continuous bioprocessing market is expected to grow at a CAGR of 23.0% from 2020 to 2027 to reach $348.9 million by 2027.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, challenges, and opportunities. Some of the major factors driving this market's growth include the growing demand for biopharmaceuticals, technological developments in continuous bioprocessing, product launches in the area of continuous bioprocessing, and global initiatives supporting the adoption of biopharmaceuticals. The growing shift towards the bioprocess 4.0 industry, growing opportunities in developing countries, and rising preference for personalized medicine are expected to create significant market growth opportunities.
Based on product, the filtration systems and consumables segment accounted for the largest share of the market in 2020. The growing demand for higher standards of filter operations in biopharma manufacturing is one of the major drivers for the growth of this segment. Filter manufacturers are developing filtration technologies for continuous bioprocessing to achieve both separation and purification through a combination of physical removal capabilities of filtration and size exclusion.
Based on application, the research and development segment is expected to grow at the highest CAGR during the forecast period. The rising focus of R&D to develop vaccines and suitable therapies for COVID-19 and growing relevance of mAb manufacturing for the treatment of various diseases are driving the market growth. The R&D in cell and gene therapy is also accelerated, with over 900 candidates in clinical studies. Facility expansions of CROs or CDMOs to advance research in these areas are expected to boost market growth.
Based on end user, the CDMOs and CROs segment is expected to grow at the highest CAGR during the forecast period. Rising investments in CDMOs and CROs and the gradual shifting of CDMOs from batch to continuous manufacturing are driving the market growth.
An in-depth analysis of the continuous bioprocessing market's geographical scenario provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2020, North America commanded the largest share of the global continuous bioprocessing market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The factors such as an established healthcare system in North America, greater adoption of advanced technologies, growth in pharmaceutical research & development, and strong presence of key players are contributing to the largest share of this region.
Some of the key players operating in the global continuous bioprocessing market are 3M (U.S.), Cytiva (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), Repligen Corporation (U.S.), Eppendorf AG (Germany), Applikon Biotechnology (Netherlands), Pall Corporation (U.S.), and Bionet (Spain).
Scope of the Report:
Global Continuous Bioprocessing Market, by Product
- Filtration Systems and Consumables
- Chromatography Systems and Consumables
- Bioreactors
- Sterilizers
- Centrifuges
- Incubators and Shakers
- Mixing systems
- Cell Culture Media, Buffers, and Reagents
- Other instruments and consumables
Global Continuous Bioprocessing Market, by Application
- Commercial
- Vaccines
- mAb production
- Recombinant Protein Production
- Cell and Gene Therapy Production
- R&D
Global Continuous Bioprocessing Market, by End User
- Pharmaceutical and Biotechnology Companies
- Contract Development and Manufacturing Organizations and Contract Research Organizations
- Academic and Research Institutes
Global Continuous Bioprocessing Market, by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- China
- Japan
- India
- Rest of APAC (RoAPAC)
- Latin America
- Middle East & Africa
Table of Contents
1 Introduction
2 Research Methodology
4 Market Insights
5 Global Continuous Bioprocessing Market, By Product
6 Global Continuous Bioprocessing Market, By Application
7 Global Continuous Bioprocessing Market, By End User
8 Continuous Bioprocessing Market, By Geography
9 Competitive Landscape
10 Company Profiles (Business Overview, Product Portfolio, Financial Overview, and Strategic Developments)
11 Appendix
List of Tables
List of Figures
Companies Mentioned
- 3M (U.S.)
- Cytiva (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- Merck KGaA (Germany)
- Sartorius AG (Germany)
- Repligen Corporation (U.S.)
- Eppendorf AG (Germany)
- Applikon Biotechnology (Netherlands)
- Pall Corporation (U.S.)
- Bionet (Spain).
